darunavir has been researched along with dolutegravir in 49 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (dolutegravir) | Trials (dolutegravir) | Recent Studies (post-2010) (dolutegravir) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 1,128 | 179 | 1,105 |
| Protein | Taxonomy | darunavir (IC50) | dolutegravir (IC50) |
|---|---|---|---|
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Solute carrier family 22 member 2 | Homo sapiens (human) | 1.9 | |
| Integrase | Human immunodeficiency virus 1 | 0.0414 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (51.02) | 24.3611 |
| 2020's | 24 (48.98) | 2.80 |
| Authors | Studies |
|---|---|
| Lacombe, K; Surgers, L | 1 |
| Arribas, JR; Pozniak, AL | 1 |
| Antinori, A; Brennan, C; Clotet, B; Dumitru, I; Fehr, J; Feinberg, J; Fujiwara, T; Harris, J; Khuong-Josses, MA; Min, S; Ortiz, R; Pokrovskiy, V; Saag, M; van Lunzen, J | 1 |
| Bigoloni, A; Boeri, E; Castagna, A; Cavarelli, M; Galli, A; Mainetti, L; Nozza, S; Pignataro, AR; Sampaolo, M; Scarlatti, G; Tolazzi, M | 1 |
| Martin-Carpenter, L; Quercia, R; Roberts, J; Zala, C | 1 |
| Brennan, C; Cavassini, M; Clotet, B; de Oliveira, CF; Givens, N; Henry, K; Kulagin, V; Lazzarin, A; Molina, JM; van Lunzen, J | 1 |
| Baldin, GM; Capetti, AF; Cattelan, AM; Cenderello, G; Cima, S; Cossu, MV; De Socio, GV; Niero, FP; Riccardi, N; Rizzardini, G; Rusconi, S; Sasset, L; Sterrantino, G | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Capetti, A; Cattaneo, D; Clementi, E; Cozzi, V; Gervasoni, C; Riva, A; Rizzardini, G | 1 |
| Boesecke, C; Degen, O; Klinker, HHF; Krznaric, I; Kümmerle, T; Schwerdtfeger, C; Spinner, CD; Wolf, E; Zink, A | 1 |
| Baldin, GM; Barbarini, G; Capetti, AF; Cattelan, AM; Cenderello, G; Cossu, MV; De Socio, GV; Niero, FP; Orofino, G; Riccardi, N; Rizzardini, G; Rusconi, S; Soria, A; Sterrantino, G | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Boswell, R; Foisy, MM; Hughes, CA | 1 |
| Becker, M; Chan, S; Harrigan, PR; Kasper, K; Keynan, Y; Wheeler, J | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Amara, A; Bisdomini, E; Boffito, M; Cerrone, M; Elliot, ER; Else, L; Khoo, S; Owen, A | 1 |
| Cabot, JF; Denault, JS; Langlois, H; Marcotte, S; Sheehan, NL | 1 |
| Bociąga-Jasik, M; Cielniak, I; Firląg Burkacka, E; Gąsiorowski, J; Horban, A; Jabłonowska, E; Kalinowska, A; Piątek, A; Siwak, E; Wójcik-Cichy, K | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Baldin, GM; Barbarini, G; Capetti, AF; Cattelan, A; Celesia, BM; Cenderello, G; Cossu, MV; De Socio, GV; Niero, FP; Riccardi, N; Rizzardini, G; Rusconi, S; Soria, A; Sterrantino, G | 1 |
| Dunn, KJ; Kagan, RM; Kaufman, HW; Nettles, RE; Snell, GP | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Rojo, A; Vivancos, MJ; Vizcarra, P | 1 |
| Be, G; Chiesi, S; Lanzafame, M; Lattuada, E; Piacentini, D; Rizzardo, S; Tacconelli, E | 1 |
| Alves Saldanha, S; Battegay, M; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M | 1 |
| Beum, R; Gardner, EM; Hawkins, KL; Johnson, S; McLees, MP; Montague, BT; Rowan, SE | 1 |
| Atzori, C; Baldelli, S; Cattaneo, D; Cozzi, V; Filice, C; Fusi, M; Gervasoni, C; Micheli, V | 1 |
| Allavena, C; Cheret, A; Cotte, L; Delobel, P; Duvivier, C; Goujard, C; Lascoux Combe, C; Meyer, L; Poizot-Martin, I; Rey, D; Reynes, J; Seng, R; Surgers, L; Tran, L; Veil, R | 1 |
| Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T | 1 |
| Kourkounti, S; Paparizos, V; Vasalou, V | 1 |
| Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M | 1 |
| Cattaneo, D; Gervasoni, C; Giacomelli, A; Mancon, A; Micheli, V | 1 |
| Balogh, A; Bidner, H; Boesecke, C; Klinker, HHF; Schneider, J; Spinner, CD; Weidlich, S; Wolf, E; Zink, A | 1 |
| Beloumou, G; Billong, SC; Bissek, AZ; Cham, F; Colizzi, V; Dambaya, B; Elat, JN; Etame, MMN; Fokam, J; Kamgaing, N; Kamgaing, R; Mossiang, L; Moudourou, S; Moussi, EE; Nanfack, AJ; Ndjolo, A; Ngako Pamen, JN; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Temgoua, ES; Teto, G | 1 |
| Cazzaniga, A; Galli, M; Maier, J; Rusconi, S; Scrimieri, R | 1 |
| Antinori, A; Armenia, D; Berno, G; Borghi, V; Bouba, Y; Ceccherini-Silberstein, F; Cicalini, S; Fabeni, L; Gagliardini, R; Mussini, C; Perno, CF; Santoro, MM; Vergori, A | 1 |
| Aboura, R; Benaboud, S; Bouazza, N; Boujaafar, S; Foissac, F; Gana, I; Hirt, D; Lui, G; Treluyer, JM; Zheng, Y | 1 |
| Boesecke, C; Bührlen, B; Cordes, C; Fischer, F; Heiken, H; Jensen, BE; Krznaric, I; Kümmerle, T; Olliges, E; Ronel, J; Schneider, J; Scholten, S; Spinner, CD; Stellbrink, HJ; Weidlich, S; Wolf, E | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Castelnuovo, B; Hakim, J; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Mirembe, G; Mugerwa, H; Musaazi, J; Paton, NI; Siika, A; Tukamushabe, P; Walimbwa, S | 1 |
| Balogh, A; Bidner, H; Boesecke, C; Cordes, C; Heiken, H; Krznaric, I; Kümmerle, T; Schneider, J; Spinner, CD; Stellbrink, HJ; Wolf, E | 1 |
| Ajana, F; Avettand-Fenoel, V; Bauer, R; Charre, C; Cheret, A; Cua, E; Gardiennet, E; Lacombe, K; Mariaggi, AA; Meiffredy, V; Meyer, L; Pialoux, G; Rouzioux, C | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Alcantarini, C; Bono, V; Bonora, S; Calcagno, A; Cannizzo, ES; Cusato, J; D'Avolio, A; De Nicolò, A; De Vivo, E; Di Perri, G; Ferrara, M; Ianniello, A; Marchetti, G; Nozza, S; Salvador, E; Trentalange, A; Trunfio, M | 1 |
| Abdalla, S; Coelho, A; Compagnucci, A; Cressey, TR; Hirt, D; Ramos, JT; Riault, Y; Saidi, Y; Tréluyer, JM; Zheng, Y | 1 |
| Borghetti, A; Borghi, V; Bruzzone, B; Callegaro, A; Ciccullo, A; Di Biagio, A; Di Giambenedetto, S; Farinacci, D; Gennari, W; Rusconi, S; Salvo, PF; Saracino, A; Vicenti, I; Zazzi, M | 1 |
| Antinori, S; Cattaneo, D; Gervasoni, C; Gori, A; Micheli, V; Pagano, S | 1 |
| Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Colafigli, M; Di Giambenedetto, S; Fabbiani, M; Farinacci, D; Lagi, F; Masini, M; Montagnani, F; Mussini, C; Panza, F; Rossetti, B; Sterrantino, G; Tumbarello, M | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
4 review(s) available for darunavir and dolutegravir
| Article | Year |
|---|---|
Hepatoxicity of new antiretrovirals: a systematic review.
Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles | 2013 |
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipids; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Ritonavir; Time Factors; Treatment Outcome | 2015 |
Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Observational Studies as Topic; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2018 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
12 trial(s) available for darunavir and dolutegravir
| Article | Year |
|---|---|
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-HIV Agents; Creatinine; Darunavir; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Serum Albumin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Plasma; Prospective Studies; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome | 2017 |
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Young Adult | 2019 |
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Topics: Adult; Aged; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reproducibility of Results; Salvage Therapy | 2018 |
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Topics: Anti-HIV Agents; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Quality of Life; Ritonavir; Viral Load | 2022 |
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Resistance; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult; Zidovudine | 2021 |
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2021 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load | 2022 |
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Pyridones; Ritonavir | 2023 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
33 other study(ies) available for darunavir and dolutegravir
| Article | Year |
|---|---|
FLAMINGO: how much rosier can antiretroviral therapy get?
Topics: Anti-HIV Agents; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides | 2014 |
Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemokine CCL5; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Envelope Protein gp120; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Oxazines; Peptide Fragments; Phylogeny; Piperazines; Pyridones; Receptors, CCR5; Receptors, CXCR4; Ritonavir; Sulfonamides; Triazoles; Viral Load; Viral Tropism | 2014 |
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Drug Resistance, Viral; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retreatment; Ritonavir; RNA, Viral; Salvage Therapy; Viral Load; Virus Replication; Young Adult | 2017 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir | 2017 |
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada.
Topics: Adult; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies; Treatment Outcome; Viral Load | 2018 |
Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Topics: Anti-Retroviral Agents; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Quinolones | 2019 |
Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Viral Load | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Topics: Anti-HIV Agents; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2019 |
Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2019 |
Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report.
Topics: Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pyridones; Viral Load; Young Adult | 2019 |
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Topics: Aged; Aged, 80 and over; Aging; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Viral Load | 2020 |
Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
Topics: Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2019 |
Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Atazanavir Sulfate; Carbamazepine; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Oxcarbazepine; Piperazines; Pyridones | 2020 |
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
Topics: Adult; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Logistic Models; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Viral Load | 2020 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome | 2020 |
Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Topics: Adult; Aged; CD4 Lymphocyte Count; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2019 |
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome | 2020 |
Multidrug-resistant HIV viral rebound during early syphilis: a case report.
Topics: Anti-HIV Agents; Coinfection; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Oxazines; Phylogeny; Piperazines; Pyridones; RNA, Viral; Sexual and Gender Minorities; Syphilis; Treponema pallidum; Viral Load | 2020 |
Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Ritonavir | 2020 |
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Topics: Aged; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Viral Load | 2020 |
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Osteogenesis; Oxazines; Piperazines; Pyridones | 2021 |
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
Topics: Anti-HIV Agents; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2021 |
Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Raltegravir Potassium; Reproducibility of Results; Tandem Mass Spectrometry; Ultrafiltration | 2021 |
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
Topics: Darunavir; DNA; Genitalia; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; HIV Infections; Humans; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Tenofovir | 2023 |
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Humans; Infant; Mutation; RNA; Viral Load | 2023 |
Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; Humans; Pyridones | 2023 |
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; RNA; Viral Load | 2023 |